Table 1 Baseline characteristics of the study population
Total (n = 363) | E19del (n = 175) | L858R (n = 154) | Uncommon (n = 34) | p value | |
|---|---|---|---|---|---|
Age, mean ± SD | 67.6 ± 11.0 | 66.5 ± 11.8 | 69.1 ± 9.9 | 66.1 ± 10.8 | 0.076 |
Sex, male | 137 (37.7) | 68 (38.9) | 59 (38.3) | 10 (29.4) | 0.572 |
BMI, kg/m2 | 24.0 ± 3.5 | 24.2 ± 3.6 | 23.6 ± 3.3 | 25.5 ± 4.0 | 0.012 |
Smoking status | 0.691 | ||||
Never smoker | 258 (71.3) | 123 (70.3) | 109 (71.2) | 26 (76.5) | |
Ex-smoker | 76 (21.0) | 36 (20.6) | 35 (22.9) | 5 (14.7) | |
Current smoker | 28 (7.7) | 16 (9.1) | 9 (5.9) | 3 (8.8) | |
Stage | 0.361 | ||||
Stage III | 31 (8.5) | 15 (8.6) | 11 (7.1) | 5 (14.7) | |
Stage IV | 332 (91.5) | 160 (91.4) | 143 (92.9) | 29 (85.3) | |
Previous chemotherapy | 0.442 | ||||
0 | 292 (80.4) | 137 (78.3) | 126 (81.8) | 29 (85.3) | |
1 | 61 (16.8) | 34 (19.4) | 24 (15.6) | 3 (8.8) | |
≥2 | 10 (2.8) | 4 (2.3) | 4 (2.6) | 2 (5.9) | |
EGFR TKIs | 0.422 | ||||
Afatinib | 102 (28.1) | 53 (30.3) | 38 (24.7) | 11 (32.4) | |
Erlotinib | 139 (38.3) | 69 (39.4) | 61 (39.6) | 9 (26.5) | |
Gefitinib | 122 (33.6) | 53 (30.3) | 55 (35.7) | 14 (41.2) | |